• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Widely used thyroid pill may be linked to bone loss

    REUTERS

    YARAL Pharma Exclusive Supplier Of Generic Levothyroxine In U.S.

    BUSINESSWIRE

    IBSA USA: Renews Aza Muñoz Partnership For Tirosint-SOL

    BUSINESSWIRE

    Xeris announces positive results from phase 2 study of investigational XeriSo

    PHARMABIZ

    Xeris Positive Phase 2 Data Once-Weekly Levothyroxine XP-8121

    BUSINESSWIRE

    Food And Drug Administration Grants Two New Label Changes To Tirosint

    BUSINESSWIRE

    Enforcement Report - Week of November 15, 2023

    FDA

    Zydus Lifesciences gets USFDA nod to market generic drug

    ECONOMIC TIMES

    Enforcement Report - Week of March 8, 2023

    FDA

    Enforcement Report - Week of March 1, 2023

    FDA

    FDA Confirms Paragraph IV Patent Litigation for Levothyroxine Sodium Oral Solution

    FDA

    Enforcement Report - Week of February 22, 2023

    FDA

    IBSA Pharma Inc. Issues Voluntary Nationwide Recall of Select Lots of TIROSINT®-SOL (levothyroxine sodium) Oral Solution Due to Subpotency

    FDA

    Ascent`s Generic Levothyroxine Sodium Receives Approval in the U.S.

    FDA

    Macleods` Generic Levothyroxine Sodium Receives Approval in the U.S.

    FDA

    Xeris taking subcutaneous challenger to AbbVie drug into phase 2

    FIERCEPHARMA

    Xeris Announces Plans for PII Study for Investigational SC Levothyroxine

    BUSINESSWIRE

    FDA Confirms Paragraph IV Patent Litigation for Levothyroxine Sodium Oral Solution

    FDA

    FDA Confirms Paragraph IV Patent Litigation for Levothyroxine Sodium Capsules

    FDA

    French drug agency says under investigation over Merck`s Levothyrox

    REUTERS

    Zydus` Generic Levothyroxine Sodium Receives Approval in the U.S.

    FDA

    Xeris Announces Positive PI Data of Investigational SC Levothyroxine

    BUSINESSWIRE

    FDA Confirms Paragraph IV Patent Challenge of Levothyroxine Sodium

    FDA

    New Study Confirms That A Commonly Used Acid-Reducing Drug Does Not Interfere

    PRNEWSWIRE

    Pharmacokinetic Study Confirming the Bioequivalence of a Novel Oral Solof

    PRNEWSWIRE

    MHRA Class 2 Medicines Recall: Levothyroxine 50mcg tablets

    MHRA

    Xeris Completes Enrollment of Its Phase 1 Study of Levothyroxine (XP-8121)

    BUSINESSWIRE

    Older Therapies Aren’t Necessarily Better for Thyroid Hormone Replacement

    FDA

    New Study Confirms the Stability and Potency of a Novel Formulation

    PRNEWSWIRE

    New Study Confirms the Stability and Potency of a Novel Formulation

    PRNEWSWIRE

    Combination thyroid hormone therapies treat hypothyroidism levothyroxine

    EUREKALERT

    Vertice launches THYQUIDITY™ (levothyroxine sodium) Oral Solution

    PRNEWSWIRE

    Teva Pharms USA`s Generic Levothyroxine Sodium Receives Approval In US

    FDA

    MannKind and Vertice to Co-Promote Thyquidity™ (levothyroxine sodium)

    MANNKINDCORP

    MannKind and Vertice to Co-Promote Thyquidity™ (levothyroxine sodium)

    PRESS RELEASE

    Lannett Launches Authorized Generic of Tirosint® (Levothyroxine Sodium Capsules)

    PRNEWSWIRE

    Good real-world outcomes for generic levothyroxine, despite narrow index

    RAPS

    Enforcement Report - Week of September 23, 2020

    FDA

    Acella Pharmaceuticals, LLC Issues Recall NP Thyroid®15 & 120 Due to Sub Potency

    FDA

    Lannett Announces Launch Of FDA Approved Levothyroxine Tablets

    PHARMABIZ

    Lannett & Cediprof Announce Distribution Agreement For An Approved Levothyroxine

    PRNEWSWIRE

    Class 2 Medicines Recall: Wockhardt UK Ltd, Levothyroxine 100micrograms

    GOVUK

    Lupin receives US FDA marketing approval for levothyroxine sodium tablets

    PHARMABIZ

    FDA Confirms Paragraph IV Patent Challenge of Tirosint 21924 (Levothyroxine Sodium) Capsules 88 mcg, 100 mcg and 125 mcg

    FDA

    Lannett Enters Into Advisory Services Agreement With Strategic Alliance Partner

    PR NEWSWIRE

    Copycats wanted: Pfizer, AZ and more under threat as China solicits generics

    FIERCE PHARMA

    Lupin launches Levothyroxine Sodium tablets in US

    ECONOMIC TIMES

    Amneal Pharm`s Generic Levothyroxine Sodium Receives Approval in US

    FDA

    Enforcement Report - Week of December 26, 2018

    FDA

    Maia Pharms` Generic Levothyroxine Sodium Receives Approval in US

    FDA

    Enforcement Report - Week of December 19, 2018

    FDA

    Foothills Professional Pharmacy Receives FDA Form 483

    FDA

    Enforcement Report - Week of October 24, 2018

    FDA

    Recipharm Ltd. Fails EDQM Inspection

    EDQM

    Enforcement Report - Week of October 17, 2018

    FDA

    Maia Pharms` Generic Levothyroxine Sodium Receives Tentative Approval in US

    FDA

    Ritonavir-containing products: reports of interaction with levothyroxine

    GOV UK

    Ritonavir-containing products: reports of interaction with levothyroxine

    GOV UK

    Ritonavir-containing products: reports of interaction with levothyroxine

    GOV UK

    Lannett loses big distribution deal, cuts 50 jobs at API plant

    FIERCE PHARMA

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.